PDF(Pubmed)
Abstract：
The management of psoriasis in individuals with human immunodeficiency virus (HIV) presents a unique challenge, marked by a more severe progression and limited efficacy of first- and second-line treatments. Although conventional systemic therapies might be considered, these agents are immunosuppressants, making their use challenging in people living with HIV (PLHIV). Biologic agents are frequently used in individuals with moderate-to-severe psoriasis, but their efficacy and safety data in PLHIV are very limited, as this patient group tends to be excluded from clinical trials. Risankizumab is a selective interleukin-23 (IL-23) inhibitor that has demonstrated a favourable safety profile and high efficacy in long-term studies and clinical practice. This current case report presents two clinical cases of PLHIV with plaque psoriasis who were effectively treated with the biologic agent risankizumab, with no reported safety issues. Although there are limited data on the use of biologics in PLHIV, this case series suggests that IL-23 inhibitors, namely risankizumab, might be a valuable therapeutic option for this population. Additional research and larger studies are needed to gain a more comprehensive understanding of the long-term safety and efficacy of IL-23 inhibitors in individuals affected by HIV.
摘要：
人类免疫缺陷病毒（HIV）个体的牛皮癣的管理提出了独特的挑战，以更严重的进展和一线和二线治疗的疗效有限为标志。尽管可以考虑常规的全身疗法，这些药物是免疫抑制剂，使其在艾滋病毒感染者（PLHIV）中的使用具有挑战性。生物制剂经常用于中度至重度银屑病患者，但是它们在PLHIV中的功效和安全性数据非常有限，因为该患者组倾向于被排除在临床试验之外。Risankizumab是一种选择性白介素-23（IL-23）抑制剂，在长期研究和临床实践中表现出良好的安全性和高疗效。目前的病例报告介绍了两例PLHIV斑块状银屑病的临床病例，这些病例均使用生物剂risankizumab进行了有效治疗。没有报告的安全问题。尽管在PLHIV中使用生物制剂的数据有限，这个病例系列表明IL-23抑制剂，即risankizumab，可能是这个人群的一个有价值的治疗选择。需要更多的研究和更大规模的研究来更全面地了解IL-23抑制剂在受HIV影响的个体中的长期安全性和有效性。
